<DOC>
	<DOCNO>NCT01666743</DOCNO>
	<brief_summary>The purpose study determine safety efficacy ceftaroline fosamil elderly subject community-acquired bacterial pneumonia ( CABP ) receive antibiotic therapy hospital .</brief_summary>
	<brief_title>Safety Efficacy Study Ceftaroline Elderly Subjects With Community-Acquired Bacterial Pneumonia</brief_title>
	<detailed_description>This multicenter study ceftaroline fosamil elderly subject ( ≥ 65 year age ) CABP . Adjunctive macrolide therapy use Investigator 's discretion . A switch oral treatment may allow discretion Investigator . The total duration therapy 5 7 day ; minimum 48 hour study drug require .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>1 . Male female ≥ 65 year age . 2 . Presence CABP warrant hospitalization . 3 . Acute illness ≥ 2 clinical sign symptom low respiratory tract infection . 4 . Radiographically confirm pneumonia . 1 . History hypersensitivity allergic reaction βlactam macrolide antibacterial agent . 2 . Confirmed suspected respiratory tract infection due solely atypical bacterial , mycobacterial , viral , fungal pathogen . 3 . More 24 hour potentially effective antibacterial therapy within 96 hour prior enrollment . 4 . Life expectancy &lt; 30 day presence order Do Not Resuscitate ( DNR ) . 5 . Evidence significant hematologic , hepatic , immunologic impairment .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Community-Acquired Pneumonia</keyword>
	<keyword>Lung</keyword>
	<keyword>Adult</keyword>
	<keyword>Infections</keyword>
</DOC>